key: cord-0020396-alnd266n
authors: Sliepen, Kwinten; Schermer, Edith; Bontjer, Ilja; Burger, Judith A.; Lévai, Réka Felfödiné; Mundsperger, Philipp; Brouwer, Philip J. M.; Tolazzi, Monica; Farsang, Atilla; Katinger, Dietmar; Moore, John P.; Scarlatti, Gabriella; Shattock, Robin J.; Sattentau, Quentin J.; Sanders, Rogier W.
title: Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers
date: 2021-08-17
journal: NPJ Vaccines
DOI: 10.1038/s41541-021-00364-x
sha: 78fec7124851035ffe7093bfc20b8eb74d298d9b
doc_id: 20396
cord_uid: alnd266n

The immunogenicity of HIV-1 envelope (Env) trimers is generally poor. We used the clinically relevant ConM SOSIP trimer to compare the ability of different adjuvants (squalene emulsion, ISCOMATRIX, GLA-LSQ, and MPLA liposomes) to support neutralizing antibody (NAb) responses in rabbits. The trimers were administered as free proteins or on nanoparticles. The rank order for the adjuvants was ISCOMATRIX > SE > GLA-LSQ ~ MPLA liposomes > no adjuvant. Stronger NAb responses were elicited when the ConM SOSIP trimers were presented on ferritin nanoparticles. We also found that the GLA-LSQ adjuvant induced an unexpectedly strong antibody response to the ferritin core of the nanoparticles. This “off-target” effect may have compromised its ability to induce the more desired antitrimer antibodies. In summary, both adjuvants and nanoparticle display can improve the magnitude of the antibody response to SOSIP trimers but the best combination of trimer presentation and adjuvant can only be identified experimentally.

The need for an HIV-1 vaccine is undebated but formidable scientific challenges have hampered the development of a vaccine. Neutralizing antibodies (NAb) responses correlate with protection for many licensed antiviral vaccines 1 but HIV-1 NAbs have been difficult to induce by vaccination. Given the huge viral sequence diversity, an HIV-1 vaccine would have to induce broadly neutralizing antibodies (bNAbs), i.e., NAbs that can cope with global, or at a minimum regional, HIV-1 diversity 2 . HIV-1 NAbs and bNAbs do develop during natural HIV-1 infection providing evidence that the human immune system can generate such antibodies 3 .

The induction of NAb responses against relatively neutralization-resistant (Tier 2) viruses by vaccination was facilitated by the design of stable soluble mimics of the native Env trimer, such as BG505 SOSIP.664 4 . Structure-based design led to newer generations of recombinant native-like trimers as well as trimers from circulating strains [5] [6] [7] [8] . Immunogens based on consensus sequences might also be valuable in vaccine strategies aimed at inducing bNAbs, since consensus sequences are usually closer to circulating isolates than circulating isolates are to one another. Moreover, rare isolate-specific antigenic determinants are eliminated, favoring, at least in theory, more cross-reactive responses 9, 10 . An example is the ConM SOSIP.v7 trimer that is based on a consensus sequence of all group M virus isolates. ConM SOSIP.v7 induces strong NAb responses against artificial consensus-based viruses. These NAb responses target the trimer apex, an epitope that might be an appropriate vaccine component to drive neutralization breadth 11 . Therefore, ConM SOSIP.v7 is now being evaluated in three human clinical trials (clinical trial.gov: NCT03961438, NCT03816137, NCT04046978).

While important steps have been made in generating immunogens that mimic the native Env trimer and induce NAbs, these immunogens do not address the relatively poor overall magnitude and durability of anti-Env responses, properties that appear to be independent from the antigenic conformation of Env immunogens 12 . Env is a notoriously poor immunogen in comparison with other pathogen-based immunogens 13 . Induction of a robust autologous Tier 2 NAb response usually requires at least three recombinant Env protein immunizations in rabbits or macaques 4, [14] [15] [16] . In contrast, vaccination with recombinant influenza hemagglutinin glycoproteins or respiratory syncytial virus glycoprotein F elicits potent neutralizing responses after only one or two immunizations 17, 18 .

The durability of Env-induced humoral responses is also poor. While the half-life of immunity induced by licensed protein subunit vaccines, such as those against tetanus and diphtheria, is 10-20 years, the half-life of anti-Env Ab responses induced by Env subunit vaccines is typically 30-60 days, i.e., >100-fold shorter 4, 19, 20 . Env has also been inferior as an immunogen in direct comparisons with influenza HA, rabies protein G and hepatitis B virus surface Ag [21] [22] [23] [24] . The reasons are poorly understood but might relate in part to the immunosuppressive effect Env has on immune cells, involving interactions of mannose glycans with C-type lectin receptors [25] [26] [27] .

Adjuvants are capable of stimulating different arms of the immune system 28 and are vital components of subunit vaccines, especially in the case of poorly immunogenic Env. However, some adjuvants are known to have adverse effects on antigen integrity. For example, some immunization studies suggest that Freund's adjuvant can denature antigens and open up cryptic epitopes that are irrelevant for inducing NAbs 29, 30 . A recent study revealed that the most commonly used adjuvants have little effect on SOSIP trimer integrity or epitope presentation 31 . However, adjuvants based on acidified alum and polyanionic CpG oligodeoxynucleotide decrease trimer stability and can block epitopes on the trimer apex, respectively.

Rabbits are commonly used in HIV-1 vaccine research because of their ability to induce NAbs against Tier 2 viruses in contrast to mice, possibly because the distribution of CDR lengths of rabbit immunoglobulins allow them to engage Env despite its extensive glycan shield 32 . Furthermore, the relatively large amounts of sera that can be obtained from rabbits allow for testing of a comprehensive number of variables. Importantly, the Env epitopes that are recognized by NAbs from rabbits are also targeted by NAbs that are induced in nonhuman primates and thus are very relevant for studying vaccine-induced NAbs in early preclinical settings 11, [33] [34] [35] . Therefore, we aimed to compare different adjuvants on the induction of HIV-1 NAbs in rabbits.

We selected four adjuvants that are used in human studies and have no or only minimal effect on Env trimer structure 31 . ISCOMATRIX is a mix of QS21 saponin, cholesterol, and phospholipid and has been tested for safety in humans and has been used widely for rabbit immunization studies 4, 32, [36] [37] [38] [39] . It is very similar to Matrix-M, the adjuvant component of Novavax' SARS-CoV-2 vaccine 40 . Second, we tested a squalene oil-in-water emulsion (SE) that is comparable to the MF59 TM adjuvant that is used in human influenza vaccines 41 . Third, we evaluated a formulation of the TLR4 ligand glucopyranosyl lipid adjuvant with liposomal QS21 (GLA-LSQ) 42 . GLA-LSQ is used with BG505 SOSIP.664 trimers in a clinical study (NCT04177355) and is similar to the AS01B adjuvant that is used in a different trial with BG505 SOSIP.664 (NCT03699241) and a trial with the germline-targeting BG505 GT1.1 trimer (NCT04224701), as well as the RTS,S malaria vaccine 43 . We also tested monophosphoryl lipid A (MPLA), another TLR4 ligand, combined with liposomes 44 . The latter adjuvant is used in clinical trials with ConM SOSIP.v7 (NCT03816137, NCT03961438).

Another established strategy to improve humoral responses is by displaying antigens on nanoparticles. Nanoparticle presentation enhances the immunogenicity of antigens by increasing their avidity and thereby improving B cell receptor cross-linking and epitope avidity. Furthermore, nanoparticle presentation improves lymph node trafficking 45, 46 . The notion that the only licensed viral protein subunit vaccines, those against hepatitis B, hepatitis E, and human papillomavirus, are virus-like particles illustrates that multimerized display of antigens is important for immunogenicity 45 . A number of nanoparticle platforms have been used to increase the immunogenicity of soluble Env trimers 47 . These platforms include the ferritin 24-mer that can present eight Env trimers 38, [48] [49] [50] , liposomes with (non-) covalently linked Env trimers 51-54 , virus-like particles 55 , and computationally designed two-component nanoparticles 56, 57 .

In this study, we systematically compared the immunogenicity of ConM SOSIP.v7 native-like trimers formulated in four different adjuvants or in the absence of adjuvant. In addition, we evaluated ConM SOSIP.v7 trimers presented on ferritin nanoparticles formulated in three different adjuvants. As expected, we found that adjuvants enhanced binding titers and the potency of the polyclonal NAb response, in particular early in the immunization regimen. Furthermore, nanoparticle presentation increased binding titers and the potency of the polyclonal NAb response, also particularly early on. Surprisingly, we found that adjuvants have different effects on the relative immunodominance/subdominance of the nanoparticle core and Env. This is relevant because we observed an inverse correlation between the relative strength of the Ab response against the nanoparticle core and the NAb response against HIV-1. Together, these results might be useful for selecting the optimal adjuvant for the induction of NAbs in particular when combining with nanoparticle display of Env trimers.

The purpose of our study was to determine the effect of different adjuvants and ferritin nanoparticle presentation on the immunogenicity of soluble Env trimers. We chose ConM SOSIP.v7 as a model antigen because it is relatively immunogenic compared to other soluble Env trimers, which allows us to detect potential differences between groups, including those that might arise early in the immunization schedule. The experimental groups are derived from three different rabbit immunization studies, including two of which we have reported on previously 11, 56 . In each study, the rabbits were immunized at the same intervals (weeks 0, 4, and 20) as used previously with other SOSIP trimers 4, 7, 8 . The rabbits were culled at week 22 when antibody levels are expected to peak. The immunogen Env doses differed less than twofold between all groups (16-30 µg Env content per dose, Fig. 1a and Fig. 2a ) across the three experiments (see Materials and methods for specific details). Here, we have analyzed these sera in binding ELISAs and ConM virus neutralization assays to assess the impact of adjuvants and ferritin nanoparticle presentation on Env immunogenicity (Figs. 1a and 2a).

In the first immunization study, six rabbits per group were immunized with 20 µg of soluble ConM SOSIP.v7 trimers (ConM trimers) with squalene emulsion (SE), MPLA liposomes, or without adjuvant. Another group received 20 µg ConM SOSIP.v7-ferritin nanoparticles (ConM-NPs) formulated in SE (16 µg Env equivalent). In the second study, five rabbits per group received 22 µg soluble ConM trimers or ConM-NPs (17 µg Env equivalent) formulated in 75 units ISCOMATRIX adjuvant 11 . In the third study, five rabbits per group received 30 µg of soluble ConM trimers or 38 µg ConM-NPs (30 µg Env equivalent) formulated in 25 µg GLA-LSQ 56 . The adjuvanted ConM trimer groups are summarized in Fig. 1A and the three ConM-NP groups are summarized in Fig. 2A .

First, we compared the humoral responses induced by the adjuvanted group of ConM trimers (n = 22 in total) to the nonadjuvanted trimers (n = 6). As expected, the adjuvanted trimer immunized rabbits induced higher binding Ab responses than rabbits immunized without adjuvants (from~6 up to~100-fold higher depending on the time point) (Fig. 1b) . We already detected midpoint binding Ab titers (EC 50 ) above 100 in most sera from adjuvanted ConM SOSIP.v7 trimer immunized rabbits after the first immunization. In contrast, to detect similar EC 50 binding titers most other adjuvanted SOSIP trimer immunogens require at least two doses 14, 16 . After the second immunization, the geometric mean titer of the combined adjuvanted trimer group was~14-fold higher than the nonadjuvanted group. As with other Env immunizations, the binding responses waned over time and were boosted by the last immunization. We did not observe differences in decay rates between adjuvanted and nonadjuvanted trimers (Fig. 1b) .

A number of rabbits elicited detectable ConM NAb responses after only one immunization (week 4, Fig. 1c ). The combined adjuvant group induced significantly higher NAb responses throughout the immunization schedule than the nonadjuvanted trimer group (~sixfold,~50-fold, and~200-fold at weeks 4, 6, and 22, respectively) (Fig. 1c) . Interestingly, binding titers did not increase with a third immunization (p = 0.63, Wilcoxon test), while neutralization titers increased significantly (p = 0.0038, Wilcoxon test) (Fig. 1d) , suggesting that the third immunization triggered additional Ab maturation.

As expected, the titers in the neutralization assays correlated strongly with titers from the binding ELISA at each time point (Spearman r = 0.84, p < 0.0001 for all datapoints combined; r = 0.68-0.85, p ≤ 0.0001 for each time point) (Fig. 1e) .

Effect of different adjuvants on ConM SOSIP trimer immunogenicity Next, we investigated the immunogenicity of the different trimer/ adjuvant combinations. Notably, sera from rabbits immunized with MPLA liposomes displayed significantly lower binding Ab responses than ISCOMATRIX at weeks 4, 16, and 20 (p = 0.025, p = 0.0071, and p = 0.0038, respectively) ( Fig. 1f and Supplementary Table 1 ). ISCOMATRIX adjuvanted trimers induced a trend toward the highest binding titers (not statistically significant) but after the third immunization the different adjuvant groups displayed no significant differences in binding titers (Fig. 1f) .

The results from neutralization assays revealed a similar picture to the binding ELISAs. Most notably, none of the rabbits that received MPLA liposomes induced ConM NAbs 4 weeks after the prime, while 12/16 rabbits receiving trimers in SE, ISCOMATRIX or GLA-LSQ adjuvants displayed NAb ID 50 titers > 100 (Fig. 1g) . At week 6, after the first boost, most rabbit sera contained strong Table 2 11, 56 . All data were generated at the AMC. Horizontal lines represent geometric mean values.

neutralization activity with most ID 50 titers > 1000 (Fig. 1g) . As expected, these titers waned over time: 16 weeks after the first boost (week 20), NAb titers of rabbits that received ISCOMATRIX were still relatively strong (all five rabbits displayed ID 50 titers > 500), while NAb titers from rabbits that received MPLA were significantly weaker (Fig. 1g) . After the third immunization we did not detect significant differences between the adjuvants (Fig. 1g) . To allow quantification of neutralization over the course of the experiment we normalized the individual ID 50 titers to the geometric mean titer of the corresponding time point (week 4, 6, 16, 20, or 22). All normalized titers from the ISCOMATRIX group were above 1.0, which indicates that all ISCOMATRIX ID 50 titers were higher than their respective geometric mean ID 50 titers at each time point.

We tested the week 22 sera against the related, but more neutralization-resistant ConS virus and the sensitive heterologous Table 2 . e Binding titer comparison of the different adjuvanted ConM-NP groups. f Neutralization titers of sera from rabbits that received ConM-NPs with either SE, ISCOMATRIX, or GLA-LSQ. g Midpoint binding titers against the ferritin cage by ConM-NP immunized rabbits. Data are represented as geomeans + geomean SD from five or six biological replicates. Stars denote significant differences between the ISCOMATRIX and SE groups by Kruskal-Wallis test, Dunn's post-test. h Relative ferritin binding by ConM-NP immunized rabbits. Ratios are derived from the midpoint binding titers of Figs. 2E and 2G. i Simple linear regression analysis of ferritin binding at week 4 (g) and ConM neutralization at week 6 (f). j Simple linear regression analysis of SOSIP binding at week 4 (e) and ConM neutralization at week 6 (f). k Simple linear regression analysis of relative ferritin binding at week 4 (h) and ConM neutralization at week 6 (f). Spearman r and p value are indicated. Stars denote statistical differences: *p < 0.05; **p < 0.01; ***p < 0.001. See also Supplementary Table 2. All data were generated at the AMC. Horizontal lines represent geometric mean values.

Tier 1 A SF162 virus. ConS is based on a consensus sequence of group M, but it contains longer variable loops that are also different in sequence compared to ConM virus 11 . At week 22, virtually all trimer immunized rabbits, except some rabbits in the nonadjuvanted and MPLA liposome adjuvanted trimer group, had developed NAb activity (ID 50 titer > 40) against ConS. None of the trimer groups showed strong neutralization against the SF162 virus or displayed neutralization breadth ( Fig. 1h and Supplementary Table S2 ).

Rabbits immunized with ConM-NP received ISCOMATRIX, SE, or GLA-LSQ adjuvants (Fig. 2a) . We compared the serum binding and neutralization titers from the rabbits that received ConM trimers with ConM-NPs by normalizing the titers for each adjuvant (Figs.  2b, 2c) . At week 4, the normalized binding titers of the combined NP group (n = 16) were slightly higher (twofold) than those of the combined trimer group (n = 16) (p = 0.0044 for the comparison). After subsequent boosts, the combined normalized binding titers were similar between the ConM trimer and ConM-NP groups (Fig.  2b) .

ConM neutralization was more strongly augmented by NP presentation than ConM binding (Fig. 2c) . The combined ConM-NP group displayed significantly stronger NAb responses at weeks 6 (~threefold, p = 0.019), 16 (p = 0.035), and 20 (p = 0.012), and we observed a trend for week 22 (p = 0.051), interestingly we did not observe a significant difference at week 4. Over the course of the experiment, ConM neutralization was~2.5-fold higher for NP immunized animals compared to trimer immunized animals (Fig.  2c , all weeks combined, p < 0.0001 for the comparison). As expected, binding Ab titers from ConM-NP immunized rabbits correlated strongly with NAb titers (Supplementary Fig. 1a) .

Furthermore, rabbits immunized with nanoparticles also displayed significantly higher neutralization activity against ConS (geometric mean ID 50 of 1368 for the NP group vs. 256 for the single trimer group, p = 0.0001) and SF162 (geometric mean ID 50 of 315 for the NP group vs. 25 for the single trimer group, p < 0.0001) (Fig. 2d) . The increased neutralization observed for SF162 probably represents anti-V3 Abs that are induced by the exposed V3-loop of uncleaved ConM SOSIP.v7 trimers that exist on ferritin nanoparticles 11 . We did not observe an improvement in neutralization breadth (Supplementary Table 2 ).

In summary, ferritin nanoparticle presentation significantly increased the immunogenicity of ConM SOSIP.v7 in rabbits.

Next, we compared the three adjuvants between the ferritin immunized animals. Overall, binding and neutralizing Ab titers were similar between SE and ISCOMATRIX nanoparticle immunized rabbits, except for the binding titers at week 16 (Figs. 2e, f) . However, GLA-LSQ with ConM-NPs induced significantly lower binding Ab and NAb responses than ISCOMATRIX at most time points (Figs. 2e, f) . Only two weeks after the third immunization (week 22), binding and neutralization titers became similar (Figs. 2e, f). Most notably, at week 4, none of the animals receiving nanoparticles with GLA-LSQ-induced NAb titers above 100, while SE and ISCOMATRIX nanoparticle immunized animals induced responses with ID 50 values of 127-4860 (Fig. 2f) . The geometric mean NAb titer of the GLA-LSQ group remained lower, even after the second immunization:~10-fold lower at week 6 (p = 0.0198 and p = 0.0194, vs. SE and ISCOMATRIX, respectively),~25-fold at week 16 (p = 0.029, versus ISCOMATRIX) and 20-fold at week 20 (p = 0.029, vs. ISCOMATRIX) (Fig. 2f) . However, after the third immunization, NAb titers between the three groups were similar (Fig. 2f) .

The proteinaceous ferritin moiety of ConM-NPs is relatively exposed and the heterologous ferritin nanoparticle can induce an antiparticle Ab response 11, 17 . B cells recognizing the ferritin moiety might compete with more useful B cells that recognize Env-specific epitopes. To investigate whether the different adjuvants impact the immunogenicity of the ferritin moiety we used an ELISA assay to measure binding Ab responses to the naked ferritin cage (Supplementary Table 3 ).

All ConM-NP immunized rabbits induced binding Ab responses to the ferritin moiety immediately after the first immunization and these responses were boosted after subsequent immunizations (Fig. 2g) . The ISCOMATRIX recipients showed significantly greater reactivity to the ferritin moiety than SE at weeks 4, 6, 16, and 20 (Fig. 2g) . When plotting the ratio of anti-ferritin titers to anti-Env titers to gauge the relative immunodominance of the two components, it is evident that GLA-LSQ causes a~12-fold shift in immunodominance of ferritin compared to SE at week 4 (p = 0.0013) and~fivefold at week 6 (p = 0.0205) (Fig. 2h) . That difference was somewhat less pronounced and not statistically significant when comparing GLA-LSQ versus ISCOMATRIX.

We wished to assess the role of pre-existing anti-NP responses on anti-Env responses. Therefore, we plotted the week four ferritin ELISA binding titers (from Fig. 2g) vs. ConM neutralization at week 6 and we observed an inverse correlation trend, which was significant when we excluded the ISCOMATRIX group (Fig. 2i) . As expected, week 4 trimer binding responses were predictive for week 6 neutralization (Fig. 2j) . Furthermore, relative ferritin binding at week 4 (from Fig. 2h ) was correlated with week 6 neutralization (r = −0.77; p = 0.0008, Fig. 2k ). At later time points, we did not observe correlations between anti-ferritin responses and neutralization. These results suggest that early anti-ferritin responses induced by ConM-NPs might interfere with the development of ConM NAb responses when using certain adjuvants. In summary, adjuvants can alter the relative immunodominance of the ferritin cage vs. the ConM SOSIP.v7 trimer.

Here, we have evaluated the effect of adjuvants and nanoparticle presentation combined with a native-like HIV-1 Env trimer immunogen on the induction of Ab responses in rabbits.

As expected, adjuvants strongly augmented the binding and neutralizing Ab responses induced by ConM SOSIP.v7 trimers compared to when no adjuvant was used. Between the four trimer adjuvant groups, binding and neutralization titers did not significant differ after the last time point (week 22). However, we found significant differences at earlier time points. Notably, after the first immunization, none of the rabbits that received MPLA liposomes induced a detectable ConM NAb response, while sera from most other rabbits did neutralize ConM efficiently after just one immunization. Overall, the adjuvant rank order for inducing NAbs using ConM SOSIP trimer in rabbits is as follows: ISCOMATRIX > SE > GLA-LSQ ≈ MPLA liposome > no adjuvant.

Nanoparticles were most immunogenic when combined with ISCOMATRIX, while they induced significantly lower anti-Env responses when combined with GLA-LSQ. Here, we have also shown that the ferritin moiety induces a rapid Ab response. This might lead to unwanted off-target anti-nanoparticle responses 13 . In contrast to its weak anti-Env response, GLA-LSQ caused a strong anti-nanoparticle response. This demonstrates that the strength of the anti-nanoparticle response depends on the adjuvant used. This might be explained by differences in antigen retention at the injection site and subsequent antigen presentation in germinal centers by adjuvant-recruited immune cells. Furthermore, SOSIP trimers combined with GLA-LSQ display a slightly decreased binding to the apex-targeting PGT145 bNAb 31 . This suggests that GLA-LSQ causes minor perturbations in the immunodominant apex of ConM SOSIP, which decreases induction of (N)Abs.

Whether or not anti-particle responses have adverse consequences for the quality of the NAb response was thus far unproven. Basic B cell immunology dictates that B cells compete in germinal centers to sequester antigen. In this case, B cells that recognize the surface of the nanoparticle compete for the same antigen as Env-specific B cells 58 . Thus, multivalent antigen display on proteinaceous nanoparticles acts as a double-edged sword: it increases immunogenicity of the antigen on display but it also introduces the nanoparticle moiety as a distraction. Previous studies have shown that pre-existing immunity to ferritin or other nanoparticles does not adversely affect Ab responses against RSV F and influenza HA antigens displayed on the same nanoparticles 17, 59 . However, our results suggest that pre-existing anti-ferritin Ab responses might decrease HIV-1 Env NAb responses (Fig. 2i) . This discrepancy might be rooted in the weaker immunogenicity of HIV-1 Env compared to influenza HA or RSV F 13 . Furthermore, the potential negative effects of pre-existing immunogenicity of the nanoparticle component might not have been detected in these studies with influenza HA and RSV F because of the limited numbers of animals in each group and the lack of diverse adjuvants.

More in-depth and focused studies will be needed to verify the role of nanoparticle responses in shaping the immunogenicity of the antigens displayed. Our study highlights that in cases when such responses are a problem, a carefully matched adjuvant might be part of the solution. Moreover, anti-nanoparticle responses can be reduced by adding glycans to mask nanoparticle epitopes 60 or by using nanoparticles with less immunogenic surfaces, such as liposomes or host cell membrane-derived virus-like particles 52, 55 .

The ferritin 24-mer we used here is a popular platform for the multivalent display of viral glycoproteins to increase their immunogenicity 11, 17, 38, 50, [61] [62] [63] . However, ferritin and many other nanoparticles fold intracellularly and this can lead to the occurrence of misfolded and non-native antigens on the surface of these nanoparticles. Indeed, SOSIP trimers on ferritin display increased binding to non-NAbs compared to their soluble counterparts 11 . Two-component nanoparticles, certain virus-like particles and liposomes enable the generation of nanoparticles that only display well-folded antigens because the antigens can be purified to high quality separately prior to mixing with the nanoparticle component 52, 59, 64 . The I53-50 nanoparticle is an excellent platform that enables the generation of two-component nanoparticles. Indeed, we recently showed that ConM SOSIP.v7 trimers on I53-50 nanoparticles induced significantly less undesired non-NAbs than ConM SOSIP.v7-ferritin probably because of the absence of uncleaved ConM SOSIP.v7 trimers that display non-NAb epitopes 11, 56 .

In summary, our results inform the design of vaccination regimens aimed at inducing NAb responses. Our data imply that selecting the adjuvant of choice requires considering the nature of the antigen itself but also the higher order organization: soluble trimer or nanoparticle.

The design and characterization of the ConM SOSIP.v7 and the ConM SOSIP.v7-ferritin proteins are described in detail previously 11 . Suspension 293 F were maintained in FreeStyle medium and transfected using 1 mg/ mL PEImax at a density of 0.8-1.2 million cells/mL with a plasmid expressing ConM SOSIP.v7 or ConM SOSIP.v7-ferritin and a plasmid encoding furin. The supernatant was harvested 7 days after transfection, centrifuged, and filtered using Steritops (0.22 μm pore size; Millipore, Amsterdam, The Netherlands). Proteins were purified by adding the CNBractivated sepharose 4B beads (GE Healthcare) carrying PGT145 to the filtered supernatant and incubated on a roller at 4°C overnight. Subsequently, the supernatant and beads were passed over an Econo-Column chromatography column (Biorad). The column was then washed with three column volumes of 0.5 M NaCl and 20 mM Tris HCl pH 8.0. Protein was eluted with 3.0 M MgCl 2 pH 7.5 and immediately buffer exchanged into TN75 buffer (75 mM NaCl, 20 mM Tris HCl pH 8.0) using a 100-kDa cut-off Vivaspin20 filter (Sartorius, Gӧttingen, Germany). The Histagged ferritin nanoparticles were expressed in FreeStyle 293 F cells and purified by gravity flow over a Ni-NTA column (Qiagen) followed by SEC over a Superdex200 10/300 GL increase column. Fractions corresponding to the size of the ferritin 24-mer were pooled and concentrated in phosphate-buffered saline (PBS).

Squalene o/w emulsion (SE) was obtained from Polymun (Klosterneuburg, Austria) and is composed of 5% w/v squalene, 0.5% w/v sorbitane trioleate, 0.5% w/v polysorbate 80 in 10 mM sodium citrate buffer (pH 6.3). MPLA lipsomes (1.0 mg/mL) were also obtained from Polymun (Klosterneuburg, Austria). ISCOMATRIX (3,233 IU/ml) was obtained from CSL Ltd., Parkville, Victoria, Australia. GLA-LSQ was obtained from IDRI and is a composition of 0.1 mg/mL GLA in liposomes and 0.04 mg/mL QS21. All adjuvants were mixed with antigen and PBS just before administration.

In a first immunization study, 24 rabbits (New Zealand White, female, four groups, 6 animals/group) were immunized under subcontract at the National Food Chain Safety Office, Directorate of Veterinary Medicinal Products (NFCSO-DVMP, Budapest, Hungary) with 20 µg of PGT145-purified ConM SOSIP.v7 protein by two intramuscular immunizations in each quadriceps at week 0, 4 and 20. The first group received a soluble ConM SOSIP.v7 trimer without adjuvant. The second and third group received the same immunogen formulated with 1:1 v/v squalene emulsion (SE) adjuvant or with 50 μL v/v MPLA liposomes (MPLA) adjuvant, respectively. The fourth group received 20 µg ConM SOSIP.v7-ferritin nanoparticles formulated in SE adjuvant. 5 mL blood samples were taken from the ear median artery at week 0, 4, 6, 16, 20, and 22. All procedures were approved by the animal ethics committee of NFCSO-DVMP.

In a second immunization study 11 , 10 rabbits (New Zealand White, female, two groups, five animals/group) were immunized with either 22 µg of ConM SOSIP.v7 trimer or ConM SOSIP.v7-ferritin nanoparticles formulated in 75 units of ISCOMATRIX adjuvant (CSL Ltd., Parkville, Victoria, Australia) by two intramuscular immunizations in each quadriceps at week 0, 4, and 20.

In a third immunization study 56 , 10 rabbits (New Zealand White, female, two groups, five animals/group) were immunized with either 30 µg of ConM SOSIP.v7 trimer or 38 µg ConM SOSIP.v7-ferritin nanoparticles formulated in GLA-LSQ adjuvant (25 µg GLA and 10 µg QS21 from IDRI) by two intramuscular immunizations in each quadriceps at week 0, 4, and 20. The second and third immunization studies were performed under subcontract at Covance (Denver, USA). The immunization procedures were carried out under the ethical guidelines and protocols approved by the Covance Institutional Animal Care and Use Committee (IACUC). All trimer and nanoparticle doses are indicated in protein content only; i.e., glycans are ignored in recording amounts. All studies were conducted under applicable laws and guidelines for animal testing.

ELISAs were performed essentially as described before 11, 56 . Purified ConM SOSIP.v7 trimers (1.0 μg/mL) were diluted in TBS and immobilized on 96well Ni-NTA ELISA plates (Qiagen) for 2 h and subsequently washed with TBS. Sera were serially diluted in 2% skimmed milk and 20% sheep serum in TBS and incubated for 2 hs. After washing with TBS, 1:3000 diluted HRPlabeled goat antirabbit IgG (111-035-144; Jackson Immunoresearch) in TBS + 2% skimmed milk was added for 1 h. Next, after washing the plates five times with TBS + 0.05% Tween-20, developing solution (1% 3,3′,5,5′tetranethylbenzidine (Sigma-Aldrich), 0.01% H 2 O 2 , 100 mM sodium acetate, and 100 mM citric acid) was added. Colorimetric development was terminated by adding 0.8 M H 2 SO 4 . For determining anti-ferritin titers, 2.0 μg/mL of naked ferritin cages 11 were coated overnight on half-well 96well plates, which were then blocked using Blocker Casein (Thermo Scientific). Half-maximal binding titers (EC 50 ) were calculated using GraphPad Prism 8.3.

TZM-bl neutralization assays were performed essentially as described elsewhere 7, 65 . TZM-bl reporter cell line was obtained through the NIH AIDS Research and Reference Reagents Program, Division of AIDS, NIAID, NIH (John C. Kappes, Xiaoyun Wu and Tranzyme Inc., Durham, NC, USA). One day prior to virus infection, 1.7 × 10 4 TZM-bl cells per well were seeded in a 96-well plate in DMEM containing 10% FCS, 1 × MEM nonessential amino acids, penicillin and streptomycin (both at 100 U/mL), and incubated at 37°C for 24 h in an atmosphere containing 5% CO 2 . To determine the neutralization activity of rabbit sera, the virus was incubated for 1 h at room temperature with heat-inactivated sera (threefold serial dilutions starting at 1:20). The mix was then added to the cells in the presence of 40 μg/mL DEAE-Dextran (Sigma) and Saquinavir, in a total volume of 200 μL. Three days later, the medium was removed and the cells were lysed in Reporter Lysis Buffer (Promega). Luciferase activity was measured using a Luciferase Assay kit (Promega) and a Glomax Luminometer according to the manufacturer's instructions (Turner BioSystems). All infections were performed in duplicate. Uninfected cells were used to correct for background luciferase activity. All data shown in the main figures were generated at the AMC. Serum from week 22 was also tested by OSR and/or DUMC (Duke University Medical Center, Durham, NC, USA) (displayed in Supplementary Table 2 ). All DUMC data in Supplementary Table 2 was published before 11, 56 . The NAb titers determined in the three labs correlated well ( Supplementary Fig. 1b-d) . The ID 50 values were determined as the sera dilution at which infectivity was inhibited by 50%. To assess the induction of autologous NAb responses, we tested the neutralizing activity of the sera against the infectious molecular clone (IMC) carrying the autologous ConM Env 11 .

Measurements were taken from distinct serum samples. We used nonparametric tests to analyze results, since most data were not normally distributed. Multiple groups were compared using a Kruskal-Wallis test followed by Dunn's post-test. When two groups were compared, an unpaired two-tailed Mann-Whitney U test was used, unless noted otherwise. Spearman's rank correlation coefficient was used to determine correlations. All statistical analyses were performed in GraphPad Prism 8.3.

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Correlates of protection induced by vaccination

Recent progress in broadly neutralizing antibodies to HIV

Broadly neutralizing antibodies against HIV-1: Templates for a vaccine

HIV-1 neutralizing antibodies induced by native-like envelope trimers

Glycine substitution at helix-to-coil transitions facilitates the structural determination of a stabilized subtype C HIV envelope glycoprotein

Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding

Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes

Improving the immunogenicity of native-like HIV-1 envelope trimers by hyperstabilization

Diversity considerations in HIV-1 vaccine selection

Polyvalent vaccine approaches to combat HIV-1 diversity

Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence

Strategies for inducing effective neutralizing antibody responses against HIV-1

Env exceptionalism: why are HIV-1 Env glycoproteins atypical immunogens? Cell Host Microbe

Sequential and simultaneous immunization of rabbits with HIV-1 envelope glycoprotein SOSIP.664 trimers from clades A, B and C

Elicitation of robust tier 2 neutralizing antibody responses in nonhuman primates by HIV envelope trimer immunization using optimized approaches

Immunogenicity in rabbits of HIV-1 SOSIP trimers from clades A, B, and C, given individually, sequentially, or in combination

Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies

Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus

Duration of humoral immunity to common viral and vaccine antigens

Role of multivalency and antigenic threshold in generating protective antibody responses

Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HIV-1

Innate IL-10 promotes the induction of Th2 responses with plasmid DNA expressing HIV gp120

Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein

Comparison of the patterns of antibody recall responses to HIV-1 gp120 and hepatitis B surface antigen in immunized mice

Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo

Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function

HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells

Key roles of adjuvants in modern vaccines

Denaturation of lysozyme by Freund's complete adjuvant

Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160

Effects of adjuvants on HIV-1 envelope glycoprotein SOSIP trimers in vitro

Murine antibody responses to cleaved soluble HIV-1 envelope trimers are highly restricted in specificity

Electron-microscopy-based epitope mapping defines specificities of polyclonal antibodies elicited during HIV-1 BG505 envelope trimer immunization

Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques

Mapping polyclonal antibody responses in non-human primates vaccinated with HIV Env trimer subunit vaccines

ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases

Meta-analysis on randomized controlled trials of vaccines with QS-21 or ISCOMATRIX adjuvant: safety and tolerability

Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity

Elicitation of neutralizing antibodies targeting the V2 apex of the HIV envelope trimer in a wild-type animal model

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

Safety of MF59 TM adjuvant

First-in-human, randomized, double-blind clinical trial of differentially adjuvanted PAMVAC, a vaccine candidate to prevent pregnancyassociated malaria

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children

Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines

Immunological basis for enhanced immunity of nanoparticle vaccines

Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

Nanoparticle vaccines for inducing HIV-1 neutralizing antibodies

Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles

Targeted selection of HIV-specific antibody mutations by engineering B cell maturation

Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers

Covalent linkage of HIV-1 trimers to synthetic liposomes elicits improved B cell and antibody responses

High-density array of well-ordered HIV-1 spikes on synthetic liposomal nanoparticles efficiently activate B cells

Particulate array of well-ordered HIV clade C Env trimers elicits neutralizing antibodies that display a unique V2 cap approach

Enhancing humoral responses against HIV envelope trimers via nanoparticle delivery with stabilized synthetic liposomes

Vaccine-elicited Tier 2 HIV-1 neutralizing antibodies bind to quaternary epitopes involving glycan-deficient patches proximal to the CD4 binding site

Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle

Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles

Factors in B cell competition and immunodominance

Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus

Immunosilencing a highly immunogenic protein trimerization domain

Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site

Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation

A nanoparticle-based HCV vaccine with enhanced potency

Plug-and-display: decoration of virus-like particles via isopeptide bonds for modular immunization

Measuring HIV neutralization in a luciferase reporter gene assay

We thank Larry Liao and Bart Haynes for donating the DNA plasmid for generating ConS. We thank Hansi Dean, Wayne Koff, Joanne Stefano and Beth Rasmussen for their contributions to rabbit study C0119-15. We thank Marielle van Breemen for technical assistance. We thank Celia LaBranche and David Montefiori for providing neutralization assay data, shown in Supplementary Table 2 (previously published in 11, 56 ). This project has received funding from the European Union's Horizon 2020 

The data that support the findings in this study are available from the corresponding author (R.W.S.) upon reasonable request.Received: 25 January 2021; Accepted: 16 July 2021;

The authors declare no competing interests.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41541-021-00364-x.Correspondence and requests for materials should be addressed to R.W.S.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.